Dexcom Report Highlights Untapped Potential in Type 2 Diabetes CGM Market
Event summary
- Dexcom released its 2026 State of Type 2 Report during EASD 2026, surveying 800 HCPs and 2,500 Type 2 diabetes patients across 8 countries.
- 89% of HCPs view CGMs as essential for Type 2 diabetes management, but 55% of patients report limited CGM awareness.
- Dexcom partnered with Team Novo Nordisk to become the official CGM provider for the all-diabetes professional cycling team.
- 94% of CGM users report managing diabetes more independently, with 93% finding CGMs easy to use.
The big picture
Dexcom's report underscores the growing recognition of CGMs in Type 2 diabetes management, but highlights significant access and awareness gaps. The partnership with Team Novo Nordisk aligns with broader industry trends of leveraging sports partnerships for health technology visibility. The strategic focus on expanding CGM use beyond Type 1 diabetes could unlock substantial market potential, particularly as GLP-1 medications gain traction.
What we're watching
- Market Penetration
- Whether Dexcom can overcome awareness and reimbursement barriers to expand CGM adoption among Type 2 diabetes patients.
- Strategic Partnerships
- How the Team Novo Nordisk partnership will impact Dexcom's brand visibility and real-world research initiatives.
- Technology Convergence
- The pace at which GLP-1 and CGM adoption will converge as a paired treatment for Type 2 diabetes.
Related topics